Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia

Conclusion Dasatinib could be an appropriate treatment option for imatinib-intolerant patients with CML, with cross-intolerance resulting in discontinuation in a few patients. Micro-Abstract Some patients with chronic myeloid leukemia (CML) are intolerant to first-line imatinib treatment. Our retrospective data analysis of 271 CML imatinib-intolerant patients from phase II and III studies examined the extent of cross-intolerance between imatinib and dasatinib. Our results have confirmed the clinical safety and efficacy of dasatinib in imatinib-intolerant CML patients, suggesting that dasatinib could be a suitable treatment choice for this population.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research